Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 18
- 试验地点
- 3
- 主要终点
- Reduction in Rating Scale (RS) pain compared to baseline. RS Pain will be assessed at 7, 14 days for all participants and after 28 and 56 days for patients continuing the extended phase of study.
研究概览
简要总结
The hypothesis behind the trial is the concept that Pregabalin is effective in reducing pain at rest in lower limb ischemia, and the study evaluates active treatment or placebo added to the regular pain regimens for these patients.
详细描述
Critical limb ischemia (CLI) is the end stage of peripheral arterial disease in the legs and is a consequence of deteriorating blood flow supply to the lower limbs. The clinical definition of CLI includes peripheral arterial disease and recurrent rest pain for at least two weeks with or without ulcers or gangrene.
In patients not amenable to revascularization - around 35% - amputation or palliative conservative care remains the options. Pain control is a vital part of any treatment of these patients. Besides being the principal conservative treatment, also patients undergoing revascularization experience severe pain both during work up and after surgery.
Experimental data indicate that pain in CLI is multimodal and to a large extent neuropathic. Still, current therapy is mostly based on opioid treatment, which clinically often affects pain moderately. The doses required to influence pain are also associated to severe side effects. Accordingly, there is a great need to improve pain control in the rather common disease CLI.
comparisons: pregabalin up to 600mg daily in addition to regular pain regimens compared to placebo and regular pain regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Rest pain, gangrene or ulcers located below the patella for a duration of at least two weeks (either one of these criteria are sufficient).
- •One measurement of: Ankle blood pressure(ABP) <70 mm Hg, an toe blood pressure(TBP) <50, or a TcPO2<45 mm Hg, or an ankle/brachial pressure index <0.7 (either one of these criteria are sufficient).
- •Informed consent obtained
排除标准
- •Age < 55 years
- •Women of childbearing potential
- •Patients already medicating with Pregabalin or Gabapentin
- •Creatinine clearance <30ml/min
- •Amputation necessary within two weeks
- •Revascularization necessary within two weeks (open vascular surgery or endovascular)
- •A medical history of clear dizziness
- •NYHA class IV heart failure
- •Known hypotension, or having a systolic arm blood pressure <120 mm Hg (two consecutive measurements with the patient lying supine)
- •Simultaneous or previous (within 30 days prior to study entry participation in a clinical study using experimental drugs or devices
- •Mental condition making the subject unable to understand the concepts and risk of the study
- •Known allergies against pregabalin
研究组 & 干预措施
A
Active intervention with pregabalin
干预措施: pregabalin (Drug)
B
placebo arm with capsule Lyrica Placebo
干预措施: placebo (Drug)
结局指标
主要结局
Reduction in Rating Scale (RS) pain compared to baseline. RS Pain will be assessed at 7, 14 days for all participants and after 28 and 56 days for patients continuing the extended phase of study.
时间窗: 1, 2, 4 and 8 weeks after randomization
次要结局
- Safety outcomes and adverse events will be examined and recorded throughout the study. Patient reported dizziness will be recorded separately in the CRF, as well as blood pressure at visits.(up to 8 weeks, as long as patients is in the study.)
- Improvement in the Short Form 36 (SF-36) parameter "bodily pain".(This parameter will be evaluated at baseline, after seven and 14 days of treatment. Patients continuing in the study will be scored also at 28 and 56 days.)
- The amount, dose and duration of concomitant pain medication use during study compared to use before study.(2 weeks after randomization)
研究者
Jonas Malmstedt
PhD
Karolinska Institutet